Bioventus to Divest BMP Development to Viscogliosi Brothers

Bioventus entered into a definitive agreement to divest its next-gen bone morphogenetic protein (BMP) development program to Viscogliosi Brothers, LLC, which will form a new company and initiate a clinical program to evaluate the technology for spinal fusion. The transaction is slated to close in 3Q18.

Bioventus acquired exclusive, worldwide...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us